Initiated mini-HTAs in Norway in the first half of 2026

Norway has a national framework for introducing new health technologies within the specialist health service, known as the "New Methods" framework. The framework supports evidence-based decisions on whether new methods should be introduced, retained, or discontinued in the Norwegian specialist health service. This framework ensures that all innovations undergo a formal Health Technology Assessment (HTA) before receiving funding approval. 

The framework operates at two levels:

• National level, where decisions are based on HTAs and made jointly by the four Regional Health Authorities;
• Local level, where decisions are based on mini-HTAs performed locally by hospitals.

Between January 1 and June 1, 2026, seven new MedTech-related mini-HTAs were initiated:

• Indication for CYP-2C19 assay when using clopidogrel;
• VARDE, a national solution for sharing interpreted genetic variants;
• Urine alpha-1-microglobulin test in patients with known or suspected kidney disease;
• Indication for CYP analyses when using SSRIs (selective serotonin reuptake inhibitors);
• Embolization for knee osteoarthritis;
• Repetitive transcranial magnetic stimulation as an adjunct to standard rehabilitation after stroke with upper limb motor deficits;
• Use of AI for screening in the mammography program.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments, specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.